A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This study will investigate the efficacy and safety of the combination of pembrolizumab and
lenvatinib in PD-L1 positive patients with TKI-resistant EGFR-mutated advanced NSCLC.